The Roswell Park pathology team reviewed 500 breast core biopsy cases provided by referring institutions in a single calendar year and found that 8% of the cases had a major discordance and 13% had a minor discordance, especially with respect to interpreting biomarkers that determine prognosis and therapeutic options.
The review of pathology reports for breast cancer can have a significant impact on patient care, making a change in 20% of the cases examined, according to study results from Roswell Park Cancer Institute (RPCI). The study, authored by Thaer Khoury, MD, and Yousef Soofi, MD, of the Department of Pathology at RPCI, was recently published in The Breast Journal.
“Surgical pathology is a dynamically changing specialty with frequently updated guidelines and classifications,” says Dr. Khoury. “This study underscores the need for a second review of the original pathologic material by a pathologist who specializes in breast cancer prior to implementation of breast cancer therapy.”
Read the news release by Roswell Park Cancer Institute: http://bit.ly/1KS8XBN
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More